A Multicenter, Phase 1B, Open-Label Study to Determine the Safety and Activity of CC-292 in Combination With Lenalidomide in Subjects With Relapsed and /or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Trial Profile

A Multicenter, Phase 1B, Open-Label Study to Determine the Safety and Activity of CC-292 in Combination With Lenalidomide in Subjects With Relapsed and /or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Spebrutinib (Primary) ; Lenalidomide
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 19 Aug 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Mar 2019 as reported by ClinicalTrials.gov
    • 24 Mar 2015 Planned End Date changed from 1 Apr 2019 to 1 Mar 2019, according to ClinicalTrials.gov record.
    • 24 Mar 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Jun 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top